SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
DVAX Analysis & Videos »
DVAX: Bull or Bear?
FDA Calendar Updates: Biomoda, Dynavax
DVAX
|
|
|
-28.96%
in
126 days
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 286 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial result...
|
Dynavax Technologies Corp.
DVAX
|
|
|
-5.80%
in
164 days
 
Last trade signal was SELL
at 2008-Dec-22
Price: $0.97
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic in...
|
Bullish on DVAX ...
DVAX
|
|
|
-29.63%
in
188 days
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified pipeline of Toll-like Receptor (TLR) product candidates primarily in the United States. Based on Dynavax?s proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. The company?s product programs are supported by global partnerships with pharmaceutical companies, such as GlaxoSmithKline, AstraZeneca AB, and Novartis Vaccines and Diagnostics, Inc, as well as funding from Symph...
|
hay hay hay
DVAX
|
|
|
+0.00%
in
0 minute
(closed on 06/03/09)
mite make me a dollar hear
|
Clinical Hold on Dynavax Drug
DVAX
-12.75%
in
515 days
We are intrigued by DynavaxÂ?s proprietary ImmunoStimulatory Sequence technology, but disappointed with the clinical hold on its lead candidate Heplisav. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was a...
|
People Bullish on DVAX
People Bearish on DVAX
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on DVAX |
More Resources
|
About Dynavax Technologies Corp.
- Answers.com
